Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BGIICC 2018 /
The best sequence of anti-HER2 therapy in metastatic breast cancer

18th - 19th Jan 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.01.18
Views: 2246

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

Dr Cortes speaks with ecancer at the 10th BGICC in Cairo about treatment sequencing for patients with HER2 positive breast cancer.

He details treatment options assessed in recent trials, including TDM1, trastuzumab emtansine and lapatinib, and control of brain metastasis.

Dr Cortes also gives his position from the conference debate on the suitability of combined adjuvant anti-HER2 therapy, arguing for.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation